Those in the private placement really are getting the great deal. For us shareholders we will not be hurt, but just won't benefit on the upside nearly as much as they will. A little jealous of them, but oh well.
Luoxis is another major expense, separate management team additional office space, etc. for ampe with no revenue until the ORP devices get approved and can be sold. that plus the cost of the ongoing trials just suggests further dilution later this year